Publication | Closed Access

Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure

Metabolic SyndromeInsulin SignalingHeart FailureDiabetes ManagementCardiovascular DiseaseGlucagon-like Peptide 1PhysiologyPharmacologyDiabetesDiabetes MellitusMedicineAtherosclerosisSodium-glucose Co-transporter 2Health Sciences